Kathryn A. Giblin
AstraZeneca (United Kingdom)(GB)AstraZeneca (Netherlands)(NL)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Machine Learning in Materials Science, Protein Structure and Dynamics, Immune Cell Function and Interaction, CAR-T cell therapy research
Most-Cited Works
- → Uncertainty quantification in drug design(2020)85 cited
- → DockStream: a docking wrapper to enhance de novo molecular design(2021)75 cited
- → The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes(2014)73 cited
- → De novo design with deep generative models based on 3D similarity scoring(2021)39 cited
- → Prospectively Validated Proteochemometric Models for the Prediction of Small-Molecule Binding to Bromodomain Proteins(2018)20 cited
- → Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor(2025)16 cited
- → New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets(2020)15 cited
- → Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity(2023)13 cited
- → Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors(2024)11 cited